Cargando…

Patient consent to publication and data sharing in industry and NIH-funded clinical trials

BACKGROUND: Participants are recruited into clinical trials under the assumption that the research will contribute to medical knowledge. Therefore, non-publication trials—and, more recently, lack of data sharing—are widely considered to violate the trust of trial participants. Existing practices reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Spence, O’Mareen, Onwuchekwa Uba, Richie, Shin, Seongbin, Doshi, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934880/
https://www.ncbi.nlm.nih.gov/pubmed/29724236
http://dx.doi.org/10.1186/s13063-018-2651-2
_version_ 1783320199378763776
author Spence, O’Mareen
Onwuchekwa Uba, Richie
Shin, Seongbin
Doshi, Peter
author_facet Spence, O’Mareen
Onwuchekwa Uba, Richie
Shin, Seongbin
Doshi, Peter
author_sort Spence, O’Mareen
collection PubMed
description BACKGROUND: Participants are recruited into clinical trials under the assumption that the research will contribute to medical knowledge. Therefore, non-publication trials—and, more recently, lack of data sharing—are widely considered to violate the trust of trial participants. Existing practices regarding patient consent to publication and data sharing have not been evaluated. Analyzing informed consent forms (ICFs), we studied what trial participants were told regarding investigators’ intention to contribute to medical knowledge, publish trial results, and share de-identified trial data. METHODS: We obtained 98 ICFs of industry-funded pre-marketing trials for all (17) antibiotics approved by the European Medicines Agency and 46 ICFs of publicly funded trials from the National Heart, Lung and Blood Institute Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC) data repository. Three authors independently reviewed ICFs to identify and extract what was stated or implied regarding: (1) publication of results; (2) sharing de-identified data; (3) data ownership; (4) confidentiality of identifiable data; and (5) whether the trial will produce knowledge that offers public benefit. Consensus was obtained from the two reviewers with the greatest overall agreement on all five measures. Disagreements were resolved through discussion among all authors. RESULTS: Four (3%) trials indicated a commitment to publish trial results; 140 (97%) did not commit to publishing trial results; six (4%) indicated a commitment to share de-identified data with third party researchers. Commitments to share were more common in publicly funded trials than industry-funded trials (7% vs 3%). A total of 103 (72%) ICFs indicated the trials will or may produce knowledge that offers public benefits, while 131 (91%) ICFs left unstated who “owned” trial data; of those with statements, the sponsor always claimed ownership. Patient confidentiality was guaranteed in 137 (95%) trials. CONCLUSIONS: Our results suggest that consent forms rarely disclose investigators’ intentions regarding the sharing of de-identified data or publication of trial results.
format Online
Article
Text
id pubmed-5934880
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59348802018-05-11 Patient consent to publication and data sharing in industry and NIH-funded clinical trials Spence, O’Mareen Onwuchekwa Uba, Richie Shin, Seongbin Doshi, Peter Trials Research BACKGROUND: Participants are recruited into clinical trials under the assumption that the research will contribute to medical knowledge. Therefore, non-publication trials—and, more recently, lack of data sharing—are widely considered to violate the trust of trial participants. Existing practices regarding patient consent to publication and data sharing have not been evaluated. Analyzing informed consent forms (ICFs), we studied what trial participants were told regarding investigators’ intention to contribute to medical knowledge, publish trial results, and share de-identified trial data. METHODS: We obtained 98 ICFs of industry-funded pre-marketing trials for all (17) antibiotics approved by the European Medicines Agency and 46 ICFs of publicly funded trials from the National Heart, Lung and Blood Institute Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC) data repository. Three authors independently reviewed ICFs to identify and extract what was stated or implied regarding: (1) publication of results; (2) sharing de-identified data; (3) data ownership; (4) confidentiality of identifiable data; and (5) whether the trial will produce knowledge that offers public benefit. Consensus was obtained from the two reviewers with the greatest overall agreement on all five measures. Disagreements were resolved through discussion among all authors. RESULTS: Four (3%) trials indicated a commitment to publish trial results; 140 (97%) did not commit to publishing trial results; six (4%) indicated a commitment to share de-identified data with third party researchers. Commitments to share were more common in publicly funded trials than industry-funded trials (7% vs 3%). A total of 103 (72%) ICFs indicated the trials will or may produce knowledge that offers public benefits, while 131 (91%) ICFs left unstated who “owned” trial data; of those with statements, the sponsor always claimed ownership. Patient confidentiality was guaranteed in 137 (95%) trials. CONCLUSIONS: Our results suggest that consent forms rarely disclose investigators’ intentions regarding the sharing of de-identified data or publication of trial results. BioMed Central 2018-05-03 /pmc/articles/PMC5934880/ /pubmed/29724236 http://dx.doi.org/10.1186/s13063-018-2651-2 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Spence, O’Mareen
Onwuchekwa Uba, Richie
Shin, Seongbin
Doshi, Peter
Patient consent to publication and data sharing in industry and NIH-funded clinical trials
title Patient consent to publication and data sharing in industry and NIH-funded clinical trials
title_full Patient consent to publication and data sharing in industry and NIH-funded clinical trials
title_fullStr Patient consent to publication and data sharing in industry and NIH-funded clinical trials
title_full_unstemmed Patient consent to publication and data sharing in industry and NIH-funded clinical trials
title_short Patient consent to publication and data sharing in industry and NIH-funded clinical trials
title_sort patient consent to publication and data sharing in industry and nih-funded clinical trials
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934880/
https://www.ncbi.nlm.nih.gov/pubmed/29724236
http://dx.doi.org/10.1186/s13063-018-2651-2
work_keys_str_mv AT spenceomareen patientconsenttopublicationanddatasharinginindustryandnihfundedclinicaltrials
AT onwuchekwaubarichie patientconsenttopublicationanddatasharinginindustryandnihfundedclinicaltrials
AT shinseongbin patientconsenttopublicationanddatasharinginindustryandnihfundedclinicaltrials
AT doshipeter patientconsenttopublicationanddatasharinginindustryandnihfundedclinicaltrials